Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source
No articles found.
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedica...
MorphoSys (FSE & NASDAQ: MOR) is a clinical-sta...
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the ...
AcelRx Pharmaceuticals, Inc. is a specialty pha...
Medivie Therapeutic is an Israeli public company, which developed Laboraide â a ...
Medivie Therapeutic is an Israeli public compan...
H&G Science aims to facilitate the safe and effective treatment of diseases. Our g...
H&G Science aims to facilitate the safe and eff...
Trovagene is a clinical-stage, oncology therapeutics company, taking a precision m...
Trovagene is a clinical-stage, oncology therape...
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicat...
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI...
Autolus is a clinical-stage, biopharmaceutical company, focused on the development...
Autolus is a clinical-stage, biopharmaceutical ...
Join the National Investor Network and get the latest information with your interests in mind.